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KidneyA National Registry Study of Patient
and Renal Survival in Adult Nephrotic
SyndromeAnna Kolb1, Peter J. Gallacher2, Jacqueline Campbell3, Martin O’Neill3, James R. Smith4,
Samira Bell2,5, Bryan R. Conway1,2, Wendy Metcalfe1, Nicola Joss6, Vishal Dey7,
Annette Alfonzo8, Michael Kelly9, Shahzad Shah10, Emily McQuarrie3,11, Colin Geddes3,11,
Jamie Traynor3,11 and Robert W. Hunter1,2; on behalf of the Scottish Renal Biopsy Registry
1Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh Bioquarter, Edinburgh, Scotland, UK; 2Centre for
Cardiovascular Science, Queen’s Medical Research Institute, Edinburgh Bioquarter, University of Edinburgh, Edinburgh,
Scotland, UK; 3The Scottish Renal Registry, Scottish Health Audits, Public Health & Intelligence, Information Services, Glas-
gow, Scotland, UK; 4Department of Renal Medicine, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, Scot-
land, UK; 5Division of Population Health and Genomics, University of Dundee, Dundee, Scotland, UK; 6Department of Renal
Medicine, Raigmore Hospital, Inverness, Scotland, UK; 7Department of Renal Medicine, University Hospital, Crosshouse,
Kilmarnock, Scotland, UK; 8Department of Renal Medicine, Victoria Hospital, Kirkcaldy, Scotland, UK; 9Department of Renal
Medicine, Dumfries & Galloway Royal Infirmary, Dumfries, Scotland, UK; 10Department of Renal Medicine, University Hospital
Monklands, Airdrie, Scotland, UK; and 11Glasgow Renal & Transplant Unit, Queen Elizabeth University Hospital, Glasgow,
Scotland, UKIntroduction: We aimed to determine the mortality rate, cause of death, and rate of end-stage kidney
disease (ESKD) in adults with nephrotic syndrome (NS).
Methods: We conducted a national registry–based study, including all 522 adults who had a kidney biopsy
for NS in Scotland in 2014–2017. We linked the Scottish Renal Registry to death certificate data. We
performed survival and Cox proportional hazards analyses, accounting for competing risks of death and
ESKD. We compared mortality rates with those in the age- and sex-matched general population.
Results: A total of 372 patients had primary NS; 150 had secondary NS. Over a median follow-up of 866
days, 110 patients (21%) died. In patients with primary NS, observed versus population 3-year mortality was
2.1% (95% CI 0.0%–4.6%) versus 0.9% (0.8%–1.0%) in patients aged <60 years and 24.9% (18.4%–30.8%)
versus 9.4% (8.3%–10.5%) in those aged $60 years. In secondary NS, this discrepancy was 17.1% (5.6%–
27.2%) versus 1.1% (0.9%–1.2%) in <60-year-olds and 49.4% (36.6%–59.7%) versus 8.1% (6.6%–9.6%) in$60-
year-olds. In primary NS, cardiovascular causes accounted for 28% of deaths, compared with 18% in the
general population. Eighty patients (15%) progressed to ESKD. Incidence of ESKD by 3 years was 8.4% (95%
CI 4.9%–11.7%) in primary and 35.1% (24.3%–44.5%) in secondary NS. Early remission of proteinuria and the
absence of early acute kidney injury (AKI) were associated with lower rates of death and ESKD.
Conclusions: Adults with NS have high rates of death and ESKD. Cardiovascular causes account for excess
mortality in primary NS.
Kidney Int Rep (2021) 6, 449–459; https://doi.org/10.1016/j.ekir.2020.10.033
KEYWORDS: cardiovascular disease; ESKD; glomerular disease; minimal-change nephropathy; mortality; nephroticsyndromeª 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Commentary on Page 246T
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International Reports (2021) 6, 449–459using small case series and in terms of short-term, dis-
ease-specific renal outcomes such as whether or not
there is remission of proteinuria. NS is associated
with progressive kidney failure, infection, thrombosis,
and cancer.1,2 A few small observational studies in
older adults have reported high death rates,3 but in
general hard, patient-centered outcomes such as death
and ESKD have not been well quantified.
To our knowledge, no nationwide studies have
systematically evaluated patient-centered outcomes in
adult NS. Indeed, a recent comprehensive review of449
CLINICAL RESEARCH A Kolb et al.: Survival in Adult Nephrotic Syndromeminimal-change nephropathy did not mention risk of
death or ESKD.4 We aimed to address this deficiency by
performing a national, registry-based data linkage
study of adults with biopsy-proven NS. We assessed
mortality rates, cause of death, and rates of progression
to ESKD.
METHODS
The methods are given in full in the Supplementary
Methods.
Design, Setting, and Participants
We conducted a retrospective, observational, registry-
based cohort study including all adults who had a
native kidney biopsy for NS in Scotland between
January 1, 2014, and December 31, 2017. We retrieved
records for biopsies in whom NS was deemed the
indication for biopsy by local clinicians. Where pa-
tients had multiple biopsies during the study period,
we included only data pertaining to the first biopsy.
Follow-up was censored on December 31, 2018.
We prespecified subgroups of interest prior to
retrieving any data. These were designed to draw
comparisons by NS etiology (primary glomerular dis-
ease vs. secondary causes), diagnosis, age (18–59
vs. $60 years), and remission of proteinuria within the
first 6 months. We published a prespecified analysis
plan on April 2, 2019 (https://www.srr.scot.nhs.uk/
Biopsy-Registry/_docs/OPRINEPH-protocol-paper.pdf).
We have adhered to the principles of this plan but have
deviated from the specifics in 2 respects. First, we were
unable to obtain high-quality data on morbidity out-
comes and drug prescription and have therefore not
included these. Second, we had originally intended to
present data for primary NS only, because of the het-
erogeneity in secondary NS. However, these data pro-
vide a useful context, and so we present data here for
all NS.
Variables, Data Sources, and Measurements
Our data sources were the National Records of Scotland
for mortality data and the Scottish Renal Biopsy Reg-
istry for all other data.5 Individual patient data from
these sources were linked through a unique national
patient identifier (CHI number). The Scottish Renal
Biopsy Registry records data for all adult kidney bi-
opsies in Scotland.6
We retrieved data on demographics (age, sex, Scottish
Index of Multiple Deprivation [SIMD] from SIMD16),
disease (glomerular diagnosis), laboratory results (serum
creatinine, serum albumin, urine protein-to-creatinine
ratio, and urine albumin-to-creatinine ratio), and renal
replacement therapy events (dialysis or kidney trans-
plant). The SIMD is a validated measure of social450deprivation derived from the patients’ address7; this is
expressed in quintiles, with the lowest (ranked 1) rep-
resenting areas with the greatest socioeconomic depriva-
tion. Laboratory results were collected on the day of
biopsy and after 1, 2, 3, 4, 6, 12, 18, and 24 months.
Estimated glomerular filtration rate (eGFR) was calculated
using the CKD-EPI equation.8
We retrieved the date and cause of death from the
information entered on death certificates. We retrieved
all of the causes of death entered in part I of the death
certificate, which permits up to 4 causes to be listed.
We classified cause of death using prespecified cate-
gories (Supplementary Table S1). Age- and sex-specific
mortality rates in the general population were taken
from publicly accessible national records.9
Definition of Renal Outcomes
Renal survival was defined as the time to the first of
any of the following events: starting dialysis, receiving
a kidney transplant or an eGFR falling to <15 ml/min at
any point during follow-up and then not returning to
>15 ml/min at subsequent time points.
AKI during the first 4 months of follow-up was
defined according to KDIGO serum creatinine criteria.10
We defined baseline creatinine as the lowest serum
creatinine concentration within the first 3 months, to
account for any AKI at the time of biopsy.
Remission of NS was classified according to KDIGO
definitions.11 When defining remission within the first
6 months, we took the lowest urine protein-to-
creatinine and albumin-to-creatinine ratios and the
highest serum albumin result within the first 6 months.
Statistical Methods
Data were analyzed in R (version 3.6.1).12 Our code is
publicly accessible (https://github.com/robertwhunter/
nephrotic_survival_SRR).
Standardized mortality was calculated as the ratio
between the observed number of deaths and the
number of deaths expected in the general population,
given the age, sex, and follow-up duration for each
patient.
Survival was determined using a survival (Kaplan-
Meier) analysis. Survival was compared between pre-
specified subgroups using a Cox proportional hazards
(CoxPH) model. We tested whether dependent vari-
ables satisfied the assumption of linearity. Age, eGFR,
hemoglobin, and SIMD quintile were broadly linear
and were therefore treated as continuous linear vari-
ables in the CoxPH model. Albumin had a nonlinear
relationship with log hazard and was dichotomized in
the final model. The urine protein-to-creatinine ratio
did not predict mortality and was excluded from the
final model. Renal survival was determined in a modelKidney International Reports (2021) 6, 449–459
A Kolb et al.: Survival in Adult Nephrotic Syndrome CLINICAL RESEARCHthat accounted for the competing risk of death. We use
Fine and Gray’s method, having first excluded patients
who had ESKD at baseline.13,14RESULTS
Participants
Across all 9 adult renal centers, there were 2811 native
kidney biopsies in 2723 patients during the study
period: an incidence of 130 biopsies per million pop-
ulation per year. A total of 556 patients were recorded
in the registry as having had a biopsy for NS. We
excluded 34 patients where case note review did not
support a diagnosis of NS or where age was <18 years,
leaving 522 patients in the final study cohort: an
annual incidence of 24.2 per million population. Pa-
tients were followed up for a median 866 days (IQR
524–1264). The median number of glomeruli sampled in
the formalin-fixed tissue was 13 (IQR 8–19). A mini-
mum of 10 glomeruli were sampled in 69% of all
biopsies.
Baseline demographic and laboratory data are pre-
sented in Table 1. Median age was 63.0 years (IQR
49.8–72.4); 46% were female. Overall, 372 patients had
a primary glomerular cause of NS; 150 had a secondary
cause. Patients with primary NS were drawn equally
from across the socioeconomic spectrum (P ¼ 0.53 for
SIMD16 quintiles by c2 test); patients with secondary
NS were more likely to come from areas with higher
socioeconomic deprivation (lower SIMD16 quintile),
although this observation may have arisen through
chance alone (P ¼ 0.07).
There was little difference between the primary and
secondary groups with respect to age, sex, serum al-
bumin, or proteinuria. Patients with secondary NS hadTable 1. Baseline demographic and laboratory data
All (n [ 522)
Demographic data







Laboratory data, median (IQR)
Alb, g/l 22.0 (16.0, 26.0)
U.PCR, mg/mmol 810 (475, 1130)
U.ACR, mg/mmol 538 (327, 802)
Cr, mmol/l 98 (72, 160)
eGFR, ml/min 62 (35, 91)
Hb, g/dl 12.7 (10.8, 14.2)
Alb, serum albumin concentration; Cr, serum creatinine; eGFR, estimated glomerular filtration ra
urine albumin-to-creatinine ratio; U.PCR, urine protein-to-creatinine ratio.
SIMD1 to SIMD5 refer to Scottish Index of Multiple Deprivation quintiles, ranging from 1 (mos
Values are n (%), unless otherwise noted.
Kidney International Reports (2021) 6, 449–459a higher serum creatinine (median 121 vs.93 mmol/l)
and lower hemoglobin (median 11.2 vs. 13.0 g/l) at the
time of biopsy.
Causative diagnoses, stratified by age, are presented
in Supplementary Figure S1 and Supplementary
Table S2. Membranous nephropathy, minimal-change
nephropathy, and focal segmental glomerulosclerosis
were the most common primary glomerular diagnoses;
all 3 diagnoses were all more common in older adults.
Diabetes, plasma cell dyscrasia, and systemic lupus
erythematosus were the commonest causes of second-
ary NS.
Mortality Rate
One hundred ten patients (21%) died during follow-
up. Death was more likely in patients with secondary
NS and in those aged$60 years (Table 2; Figure 1) (P <
0.0001 by log-rank test). Observed mortality was
higher than that predicted in the age- and sex-matched
general population (Tables 3 and 4). The standardized
mortality ratio, stratified by age and cause of NS, is
shown in Table 3. To provide a clinically relevant
assessment of absolute risk, we also calculated the 3-
year mortality and compared this to predicted 3-year
mortality in the age- and sex-matched general popu-
lation (Table 4). In patients aged $60 years with pri-
mary NS, observed versus predicted 3-year mortality
was 24.9% (95% CI 18.4%–30.8%) versus 9.4%
(8.3%–10.5%). In secondary NS, this discrepancy was
more pronounced, being 17.1% (5.6%–27.2%) versus
1.1% (0.9%–1.2%) in the <60-year-olds and 49.4%
(36.6%–59.7%) versus 8.1% (6.6%–9.6%) in the $60-
year-olds.
In a CoxPH model, increasing age, secondary NS,
and low baseline hemoglobin concentration werePrimary (n [ 372) Secondary (n [ 150)
63.5 (49.6, 72.5) 62.2 (50.5, 72.1)
161 (45) 69 (48)
78 (21) 35 (24)
64 (17) 37 (25)
70 (19) 32 (22)
84 (23) 27 (18)
72 (20) 17 (11)
21.0 (15.0, 25.8) 23.0 (18.8, 27.2)
812 (475, 1127) 804 (482, 1164)
572 (280, 829) 464 (336, 680)
93 (69, 140) 121 (84, 196)
70 (41, 93) 46 (28, 77)
13.0 (11.4, 14.4) 11.2 (9.7, 13.1)
te by CKD-EPI equation; Hb, hemoglobin concentration; IQR, interquartile range; U.ACR,
t socioeconomic deprivation) to 5 (least deprivation).
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Table 2. Summary of patient-centered outcomes stratified by cause of nephrotic syndrome and age (<60 vs. $60 years)
Whole cohort (n [ 522)
Age <60 yr Age ‡60 yr
Primary NS (n [ 157) Secondary NS (n [ 65) Primary NS (n [ 215) Secondary NS (n [ 85)
Mortality and ESKD
All death 110 (21) 3 (2) 10 (15) 51 (24) 46 (54)
All ESKD 80 (15) 13 (8) 19 (29) 22 (10) 26 (31)
ESKD then death 36 (7) 0 (0) 4 (6) 13 (6) 19 (22)
ESKD without death 44 (8) 13 (8) 15 (23) 9 (4) 7 (8)
Death without ESKD 74 (14) 3 (2) 6 (9) 38 (18) 27 (32)
Neither death nor ESKD 368 (70) 141 (90) 40 (62) 155 (72) 32 (38)
First ESKD event
Dialysis 18 (23) 6 (46) 4 (21) 2 (10) 6 (23)
Transplant 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
eGFR <15 54 (68) 6 (46) 14 (74) 14 (67) 20 (77)
eGFR <15 at baseline 7 (9) 1 (8) 1 (5) 5 (24) 0 (0)
All ESKD events
Dialysis only 42 (8) 9 (6) 11 (17) 10 (5) 12 (14)
Transplant only 1 (0) 0 (0) 0 (0) 1 (0) 0 (0)
Dialysis and transplant 11 (2) 4 (3) 5 (8) 0 (0) 2 (2)
eGFR <15 without RRT 26 (5) 0 (0) 3 (5) 11 (5) 12 (14)
None 442 (85) 144 (92) 46 (71) 193 (90) 59 (69)
ESKD, end-stage kidney disease; eGFR, estimated glomerular filtration rate by CKD-EPI equation; NS, nephrotic syndrome; RRT, renal replacement therapy.
Data are presented as n (%).
CLINICAL RESEARCH A Kolb et al.: Survival in Adult Nephrotic Syndromeassociated with mortality (Figure 2a). Risk of death in
secondary NS may be largely determined by the un-
derlying systemic disorder, and risk of death in
younger patients with primary NS is very low.
Therefore, we performed a prespecified analysis in
patients aged $60 years with primary NS. In this
model, increasing age (hazard ratio [HR] 2.32 perFigure 1. Patient survival curves, stratified by cause of nephrotic
syndrome (NS) and age. Check-marks denote times at which pa-
tients were censored from the analysis (end of follow-up). P value is
for comparison between groups by log-rank test.
452decade, 95% CI 1.37–3.94, P ¼ 0.002) and lower he-
moglobin concentration (HR 1.28 per g/l, 95% CI 1.02–
1.61, P ¼ 0.03) were associated with mortality; histo-
logic diagnosis was not (Figure 2b; Supplementary
Figure S2).
To explore which variables were most strongly
associated with death or ESKD, we constructed
sequentially adjusted models (Supplementary
Table S3). The addition of SIMD quintile had little ef-
fect on model fit, as assessed using the Akaike infor-
mation criterion, suggesting that it does not have a
strong independent association with the risk of death
or ESKD.Cause of Death
The causes of death are shown in Supplementary
Table S4 and Supplementary Figure S3. We first
considered only the single leading cause of death. In an
attempt to minimize misclassification bias, we also
performed a sensitivity analysis in which all causes ofTable 3. Difference between observed and expected mortality: age-










Primary NS, age <60 yr 157 3 1.0 3.0 (1.0–9.4)
Primary NS, age $60 yr 215 51 9.7 5.2 (4.0–6.9)
Secondary NS, age <60 yr 65 10 0.4 24.2 (13.0–44.9)
Secondary NS, age $60 yr 85 46 3.0 15.4 (11.5–20.5)
CI, confidence interval; NS, nephrotic syndrome.
Kidney International Reports (2021) 6, 449–459
Table 4. Difference between observed and expected mortality:




(mean with 95% CI)
Predicted 3-yr
mortality
(mean with 95% CI)
Primary NS, age <60 yr 0.021 (0.000–0.046) 0.009 (0.008–0.010)
Primary NS, age $60 yr 0.249 (0.184–0.308) 0.094 (0.083–0.105)
Secondary NS, age <60 yr 0.171 (0.056–0.272) 0.011 (0.009–0.012)
Secondary NS, age $60 yr 0.494 (0.366–0.597) 0.081 (0.066–0.096)
CI, confidence interval; NS, nephrotic syndrome.
The observed 3-year mortality is presented (mean with 95% CI). The expected 3-year
mortality in the age- and sex-matched general population was calculated for each
cohort (mean with 95% CI).
A Kolb et al.: Survival in Adult Nephrotic Syndrome CLINICAL RESEARCHdeath for each patient were included. Patients with pri-
mary NS were most likely to die from cardiovascular
causes, which were listed as the leading cause of death in
15 patients (28%) and as a contributory factor in 25 (46%).
Patients with secondary NS were relatively less likely to
die from cardiovascular disease andmore likely to die from
cancer. Venous thromboembolism was exceedingly un-
common as a cause of death, being listed as a contributory
factor in a single patient with secondary NS.Figure 2. Cox proportional hazards models for risk of death. Multivariable
baseline variables and death for (a) the whole study cohort and (b) the sub
albumin concentration; eGFR, estimated glomerular filtration rate calculat
Hb, hemoglobin concentration; MCD, minimal-change nephropathy; MCG
SIMD, Scottish Index of Multiple Deprivation.
Kidney International Reports (2021) 6, 449–459ESKD
Eighty patients (15%) progressed to ESKD during
follow-up. ESKD during follow-up was more common
in patients with secondary than primary NS (Table 2;
Figure 3a). There was a competing risk between pro-
gression to ESKD and death. This is evident in the
cumulative incidence functions (Figure 3b): in patients
aged <60 years, the risk of ESKD was higher than the
risk of death. In patients aged $60 years, the risk of
death was higher than that of ESKD in patients with
primary NS and equivalent to the risk of ESKD in pa-
tients with secondary NS. In a model accounting for
this competing risk, the rates of ESKD (with 95% CIs)
at 3 years were 8.4% (4.9%–11.7%) in primary NS and
35.1% (24.3%–44.5%) in secondary NS.
We constructed a multivariable model, accounting
for the competing risk of death, in patients aged $60
years with primary NS (Figure 4). This subgroup
analysis was prespecified for the reasons stated above.
In this model, lower baseline eGFR was associated with
risk of progression to ESKD (HR 2.4, 95% CI 1.6–3.6models were constructed to test the association between predictor
group with primary nephrotic syndrome aged $60 years. Alb, serum
ed by CKD-EPI equation; FSGS, focal segmental glomerulosclerosis;
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Primary NS, over 60
Secondary NS, under 60
Secondary NS, over 60
Figure 3. Proportion with end-stage kidney disease (ESKD), strati-
fied by age and cause of nephrotic syndrome (NS). (a) Event curves
were drawn using a Fine-Gray model, accounting for the competing
risk of death. Patients were censored at the end of the follow-up
period (check-marks). (b) Cumulative incidence of death or ESKD,
stratified by age and cause of NS.
CLINICAL RESEARCH A Kolb et al.: Survival in Adult Nephrotic Syndromeper 10-ml increment in eGFR, P < 0.00001) as was a
diagnosis of membranous nephropathy (HR 7.3, 95%
CI 1.1–48.7 relative to minimal change, P ¼ 0.04) or
mesangiocapillary glomerulonephritis (HR 7.6, 95% CI
1.1–49.9 relative to minimal change, P ¼ 0.04).
Association of Remission With Death and ESKD
Laboratory data are presented in Supplementary
Figure S4. Across the cohort, there was progressive454reduction in proteinuria and an increase in serum
albumin.
Overall, 238 (46%) patients achieved complete or
partial remission within 6 months; 151 (29%) patients
did not achieve even partial remission (Table 5). The
remaining patients either died within the first 6 months
or had missing follow-up proteinuria data.
Within the cohort with primary NS, the frequency
of achieving remission within 6 months was higher in
those with a diagnosis other than membranous ne-
phropathy, mesangiocapillary glomerulonephritis, or
focal segmental glomerulosclerosis (Supplementary
Table S5). We tested whether older age was associ-
ated with a reduced incidence of entering remission in
primary NS by comparing patients aged <60 years
with those aged $60 years. Overall, patients in the
younger group achieved remission slightly earlier, but
this difference was not statistically significant
(Supplementary Figure S5A and B). Similarly, there
were no statistically significant differences in time to
remission in older versus younger patients for any of
the individual primary glomerular diagnosis; the data
for minimal-change nephropathy are presented in
Supplementary Figure S5C and D.
In an analysis restricted to patients who survived 6
months after the index biopsy, entering early partial or
complete remission was associated with a progressive
reduction in the rates of death and progression to ESKD
(Supplementary Figure S6).
Association of AKI With Death and ESKD
Eighty-eight patients (17%) had an AKI at the time of
kidney biopsy. In an analysis restricted to those pa-
tients who survived for more than 4 months after bi-
opsy, 186 (39 %) developed an AKI during the first 4
months. AKI was more common in secondary NS and in
patients aged $60 years (Supplementary Table S6). An
early episode of AKI was associated with increased




We evaluated patient-centered outcomes in a national,
registry-based study of adults who underwent kidney
biopsy for NS.
We made 3 main observations. First, mortality in
this patient group is significantly higher than in the
age- and sex-matched general population. Three-year
mortality was increased by 2–4-fold in primary and
6–16-fold in secondary NS. Cardiovascular deaths were
relatively over-represented in primary NS. Second,
there were high rates of progression to ESKD, partic-
ularly in secondary NS (in whom about one-third hadKidney International Reports (2021) 6, 449–459
Figure 4. Cox proportional hazards model for risk of end-stage kidney disease (ESKD) in older patients with primary nephrotic syndrome (NS). A
multivariable model was constructed to test the association between predictor baseline variables and the onset of ESKD for the cohort with
primary NS aged $60 years. The model accounts for the competing risk of death. Alb, serum albumin concentration; eGFR, estimated
glomerular filtration rate calculated by CKD-EPI equation; FSGS, focal segmental glomerulosclerosis; Hb, hemoglobin concentration; MCD,
minimal-change nephropathy; MCGN, mesangiocapillary glomerulonephritis; SIMD, Scottish Index of Multiple Deprivation.
A Kolb et al.: Survival in Adult Nephrotic Syndrome CLINICAL RESEARCHdeveloped ESKD within 3 years). In primary NS,
baseline eGFR and glomerular diagnosis were associated
with risk of ESKD. Third, failure to achieve early
remission of NS and early AKI were both associated
with higher mortality and an increased risk of ESKD.
We presented data for all adults who had a kidney
biopsy for NS. The most valuable insights are probably
drawn from older adults with primary NS. In second-
ary NS, it is hard to draw generalizable conclusions
because clinical outcomes are driven by the causative
systemic disease and because the patient population
differs between centers depending on the prevalence of
diabetes, lupus, infectious diseases, obesity etc. Death
and ESKD are relatively uncommon in younger patients
with primary NS. However, older patients (aged $60
years) with primary NS are a relatively homogenous
group, in whom death and ESKD are common events.Table 5. Remission data, stratified by cause of nephrotic syndrome and
Whole cohort (n [ 522)
Age <60
Primary NS (n [ 157) S
Remission by 6 mo
Complete remission 76 (15) 33 (21)
Partial remission 162 (31) 65 (41)
Complete or partial 238 (46) 98 (62)
No remission 151 (29) 34 (22)
Data missing 65 (12) 18 (11)
Death before 6 mo 45 (9) 2 (1)
NS, nephrotic syndrome.
We determined the extent of any remission of nephrotic syndrome within 6 months of the bio
Data are presented as n (% of the total in that patient subgroup).
Kidney International Reports (2021) 6, 449–459We therefore focused our analysis on this group and
were able to draw conclusions that are likely to be
generalizable.
Death in Adult NS
We found that adults who underwent kidney biopsy
for NS had a 3-year mortality rate that was significantly
higher than in the age- and sex-matched general pop-
ulation. That this discrepancy was very large (up to 16-
fold) in secondary NS is not surprising because the
major causes of a secondary NS—diabetes, plasma cell
dyscrasia, systemic lupus erythematosus—are all
associated with reduced life-expectancy. The mortality
risk associated with primary NS is noteworthy and has
not been so clearly defined before.
Low baseline hemoglobin concentration was associ-
ated with an increased risk of death. It seems plausibleage
yr Age ‡60 yr
econdary NS (n [ 65) Primary NS (n [ 215) Secondary NS (n [ 85)
3 (5) 39 (18) 1 (1)
16 (25) 62 (29) 19 (22)
19 (29) 101 (47) 20 (24)
29 (45) 58 (27) 30 (35)
9 (14) 26 (12) 12 (14)
3 (5) 21 (10) 19 (22)
psy date.
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CLINICAL RESEARCH A Kolb et al.: Survival in Adult Nephrotic Syndromethat hemoglobin serves as a surrogate marker of poor
health, rather than mediating a direct causal effect on
mortality.
It is noteworthy that socioeconomic deprivation was
not associated with an increased risk of death, in
contrast to the strong association of socioeconomic
deprivation and mortality in the general population.15
This suggests that the predominant causes of death in
adults with NS override any socioeconomic drivers of
disease and is in keeping with a model in which death
is caused by aspects of the NS per se, its causative
diseases, or its treatments.
Cardiovascular death was relatively over-
represented in patients with primary NS, in whom it
accounted for 28% of deaths as the leading cause. In
the Scottish general population, cardiovascular disease
(ischemic heart disease or cerebrovascular disease)
accounted for 18% of deaths in 2018.9 Death from
cancer was relatively less common—9% in primary NS
versus 28% in the general population—presumably
predominantly because of the competing risk of car-
diovascular death.
With respect to cause of death, there were 2 note-
worthy “relevant negatives.” The proportion of deaths
caused by cancer in the cohort with secondary NS
(29%) was similar to that in the general population.
Although a Danish cohort study reported an associa-
tion between NS and a diagnosis of cancer,2 our data
suggest that cancer is not hugely over-represented as a
cause of death in adults with NS. Similarly, despite the
association of NS with venous thromboembolism,16 we
found that this was a very infrequent cause of death.
We were not able to evaluate the frequency of nonfatal
venous thromboembolism, nor to factor in the effect of
antithrombotic prophylaxis.
Renal Outcomes in Adult NS
Progression to ESKD was a relatively rare event in
primary NS (w8% by 3 years) but occurred frequently
(w35% by 3 years) in secondary NS. These data,
although not surprising given the natural history of the
diseases that cause NS, could help to inform treatment
planning decisions.
By 6 months, patients were alive and in complete or
partial remission of NS in 53% (primary NS) or 26%
(secondary NS). Only 50% of adults with minimal-
change nephropathy entered complete remission
within 6 months. This underscores the relatively
treatment-resistant nature of adult minimal-change ne-
phropathy and is worse than the remission rates re-
ported elsewhere.17,18 One potential explanation for this
discrepancy is that our population have characteristics
that are associated with an unfavorable disease outcome.
For example, our minimal-change nephropathy group456(median age 63 years) was older than many published
cohorts.17–20 Another potential explanation is that using
our registry-based approach, we included patients who
were not treated with immunosuppressive therapies: a
group frequently excluded from observational studies.
It is also possible that we have misclassified patients as
having minimal-change nephropathy when they actu-
ally had focal segmental glomerulosclerosis, but un-
likely that this will be the case for many given the
generally adequate glomerular sampling (>10 glomeruli
in 69% of all biopsies). In historic case series, remission
of minimal-change nephropathy is delayed in adults
aged $60 years.3 We made a similar observation,
although this was reasonably likely to have occurred
through chance alone in our data set (P > 0.05).
These poor outcomes, relative to childhood NS, may
reflect differences in physiological reserve or the un-
derlying glomerular disease. Minimal-change ne-
phropathy in children typically remits within days of
starting glucocorticoid treatment, whereas in adults it
often takes months to respond or fails to remit at all.21
Unsurprisingly, entering early remission was asso-
ciated with lower mortality and reduced progression to
end-stage kidney disease. This is merely an observa-
tion; only well-conducted RCTs can tell us whether
therapies that achieve early remission also improve
these hard clinical outcomes.
Within the first 4 months, 39% of our study cohort
developed AKI: a result broadly consistent with the
literature.22,23 Early AKI was associated with progres-
sion to ESKD and death. Even mild (stage 1) AKI was
associated with mortality, suggesting that this may
reflect confounding differences in patient characteris-
tics that predispose both to AKI and to death. On the
other hand, the risk of death was higher for severe
(stage 3) AKI, suggesting that there may also be a causal
relationship between AKI and death.
Strengths
Our study has all the strengths inherent in a large,
registry-based, multicenter study. We used data link-
age to ensure that we captured date and cause of death
completely and accurately.
In the largest existing study of mortality in NS, cases
were identified retrospectively using death certificate
data to find patients who had died from NS.24 How-
ever, in our study only 20 death certificates (18%)
included NS as a contributory cause of death and only
71 (65%) included any renal cause. Therefore, any
study using death certificate data to identify NS will
miss at least 35% of cases. Our prospective, registry-
based identification of cases is better placed to pro-
vide a complete picture of the risk and cause of death in
adult NS. Our cause of death data may be subject toKidney International Reports (2021) 6, 449–459
A Kolb et al.: Survival in Adult Nephrotic Syndrome CLINICAL RESEARCHmisclassification bias. However, we guarded against
that by using the most accurate source of data (i.e.,
death certificates) and by including a sensitivity anal-
ysis in which the top 4 causes of death were evaluated
and not just the leading cause.
Limitations
We acknowledge all the general limitations inherent in
an observational study in addition to the following
specific limitations.
Although we collected national data over several
years, there were small numbers in some of our
subgroups of interest. In our CoxPH models (Figures 2
and 4), this limits the precision of our HR estimates and
increases the likelihood of a type II error (i.e., we may
have been underpowered to detect real associations
between patient characteristics and mortality or ESKD).
On the other hand, in testing multiple covariates, we
may have observed associations that occurred through
chance alone (type I error). For example, it will be
interesting to see whether our observed association
between primary glomerular diagnosis and risk of
ESKD is replicated in other, larger populations.
Furthermore, in our CoxPH models, we selected
covariates a priori as being potentially clinically rele-
vant with respect to the outcomes of interest (death and
ESKD). However, we were limited to variables for
which we had good-quality data; it is likely that other
unmeasured characteristics such as smoking history
would exhibit stronger associations with these
outcomes.
We compared our mortality data to the age- and sex-
matched general population, thus not accounting for
many other potential confounding variables. The
Scottish population is predominantly white Caucasian,
and our findings may not be generalizable to other
ethnic groups.
We only studied biopsy-proven NS. Primary NS can,
by definition, only be diagnosed by kidney biopsy.
However, many cases of suspected secondary NS are not
investigated with kidney biopsy, particularly in the
context of diabetes. Therefore, our findings in biopsied
secondary NS are almost certainly not generalizable to
all patients with secondary NS.
We lack additional data thatwould help to interpret our
main findings. We were not able to capture robust data
sets pertaining to morbidity outcomes and treatment
(including immunosuppression and thromboprophylaxis).
We chose a definition of AKI that relied solely on the
serum creatinine rising (above standard thresholds) in
the first 4 months. We did not require any subsequent
recovery of renal function, as incorporating this into
the definition could have introduced a survivorship
bias, moving any association of AKI with death towardKidney International Reports (2021) 6, 449–459the null. Therefore, our definition of AKI may have
included some patients who had rapid, irreversible
progression of CKD. If so, one might expect any bias to
result in our overestimating the associations of AKI
with death and ESKD.
Implications
Our findings should be used to help patients and their
clinicians to make treatment decisions. Planning for
ESKD management (renal replacement therapy or con-
servative care) should be actively pursued, particularly
in patients with secondary NS. Advance care planning
for end-of-life care may be appropriate, particularly in
older patients and even in primary glomerular diseases
like minimal-change nephropathy. We have demon-
strated that minimal-change nephropathy is not the
benign condition that it is often considered to be.
Our findings also have implications for our under-
standing of the pathophysiology of NS and for future
research. In the cohort with primary NS, the uniformly
poor survival across disease subgroups suggests that
premature death is caused by NS per se or by the
treatment for the underlying glomerular disease. The
excess deaths were due to cardiovascular causes. The
potential drivers of this association are myriad: dele-
terious sequelae of chronic volume overload, hyper-
lipidemia or steroid therapy causing accelerated
atherosclerosis, electrolyte disturbance causing
dysrhythmia, etc. Future mechanistic and epidemio-
logic studies should attempt to determine the dominant
causative pathways. Furthermore, the excess of deaths
from cardiovascular causes provides a rationale for
interventional studies testing cardiovascular risk
reduction strategies in this patient group.
Conclusions
Adults with NS, investigated by kidney biopsy, have
increased rates of death and ESKD. Failure to achieve
early remission and early AKI are associated with death
and ESKD. In primary NS, cardiovascular deaths are
over-represented compared to the general population.
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Table S1. Cause of death coding. Causes of death were
classified into prespecified categories. The individual457
CLINICAL RESEARCH A Kolb et al.: Survival in Adult Nephrotic Syndromecauses of death assigned to each category heading are
listed.
Table S2. Age distribution of glomerular and systemic
diagnoses causing nephrotic syndrome. These same data
are presented in graphical form in Supplementary
Figure S1. FSGS, focal segmental glomerulosclerosis;
IgAN, IgA nephropathy; MCGN, mesangiocapillary
glomerulonephritis.
Table S3. Sequentially adjusted CoxPH models. These
tables demonstrate the effect of adding covariates to the
CoxPH models. The Akaike information criterion (AIC)
provides a measure of how well each model represents
that data and allows comparison between alternative
models; a lower AIC is usually preferable. (A) Mortality in
the whole cohort. (B) Mortality in patients with primary
nephrotic syndrome over age 60. (C) ESKD, accounting
for the competing risk of death, in patients with primary
nephrotic syndrome aged over 60.
Table S4. Causes of death. In the upper table, the leading
single cause of death for each patient is represented. In
the bottom table, any contributing cause of death listed
on the death certificate is included for each patient.
ESKD, end-stage kidney disease; NS, nephrotic syn-
drome; VTE, venous thromboembolism.
Table S5. Remission rate in primary nephrotic syndrome
(NS), stratified by age and primary renal disease.
Remission within the first 6 months was assessed within
the cohort of patients with primary NS. FSGS, focal
segmental glomerulosclerosis; MCGN, mesangiocapillary
glomerulonephritis.
Table S6. Acute kidney injury (AKI). Frequency of AKI
graded using the KDIGO serum creatinine criteria, during
the first 4 months of follow-up. 1ry NS, primary
nephrotic syndrome; 2ry NS, secondary nephrotic
syndrome.
Figure S1. Age distribution of glomerular and systemic
diagnoses causing nephrotic syndrome. These same data
are presented in tabular form in Supplementary
Table S2. FSGS, focal segmental glomerulosclerosis;
IgAN, IgA nephropathy; MCGN, mesangiocapillary
glomerulonephritis.
Figure S2. Patient survival in the subgroup over age 60
with primary nephrotic syndrome (NS), stratified by
glomerular diagnosis. Check-marks denote times at
which patients were censored from the analysis (end of
follow-up). P value is for comparison between groups by
log-rank test. FSGS, focal segmental glomerulosclerosis;
MCGN, mesangiocapillary glomerulonephritis.
Figure S3. Leading cause of death stratified by age and
cause of nephrotic syndrome. The leading cause of death
was determined for every patient and classified into 8
categories. VTE, venous thromboembolism.
Figure S4. Laboratory data. (A) Serum albumin (Alb), (B)
estimated glomerular filtration rate by CKD-EPI equation458(eGFR), and (C,D) urine protein:creatinine ratio (uPCR). (A–
C) Data are stratified by cause of nephrotic syndrome (NS)
and (D) by whether patients entered remission within the
first 6 months.
Figure S5. Time to remission of nephrotic syndrome,
stratified by age. Time to (A) complete or (B) partial
remission in patients with primary nephrotic syndrome.
Time to (C) complete or (D) partial remission in patients
with primary nephrotic syndrome caused by minimal
change nephropathy. Patients were censored at death or
the onset of end-stage kidney disease (check-marks). P
value is for comparison between groups by log-rank test.
Figure S6. Association of early remission with patient
survival and progression to end-stage kidney disease
(ESKD). Patients were classified according to whether their
nephrotic syndrome (NS) entered remission within the first
6 months of follow-up. Association of entering early
remission with patient survival in (A) primary NS and (B)
secondary NS. Association of early remission with ESKD in
a model accounting for the competing risk of death in (C)
primary NS and (D) secondary NS. P value is for compar-
ison between groups by log-rank test. uPCR, urine pro-
tein:creatinine ratio.
Figure S7. Association of early acute kidney injury (AKI)
with patient survival and progression to end-stage kidney
disease (ESKD). Patients were classified according to the
worst grade of AKI during the first 4 months of follow-up.
Association of early AKI with patient survival in (A) pri-
mary nephrotic syndrome (NS) and (B) secondary NS.
Association of early AKI with ESKD in a model accounting
for the competing risk of death in (C) primary NS and (D)
secondary NS. In secondary NS, there were small numbers
of patients with AKI so results were lumped into 2 groups
(AKI of any stage vs. no AKI). P value is for comparison
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